CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade - Top-Institutions - MDSpire

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • By

  • Ieva Ailte

  • Sudhir Kumar Chauhan

  • Lina Prasmickaite

  • Assia V. Bassarova

  • Amanda Poissonnier

  • Marike Feenstra

  • Marta Nyakas

  • Bjarne Johannessen

  • Truls Ryder

  • Robert Hermann

  • Lars Frich

  • Arild Holth

  • Else Marit Inderberg

  • Henrik Jespersen

  • Vivi Ann Flørenes

  • Jon Amund Kyte

  • Gunhild M. Mælandsmo

  • Eivind Valen Egeland

  • May 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Melanoma
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center (MSK)
    Memorial Sloan Kettering Cancer Center (MSK)

    New York, NY

    Key Differentiators

    • Melanoma
    • Immunotherapy

Original Source(s)

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • by Ieva Ailte, Sudhir Kumar Chauhan, Lina Prasmickaite, Assia V. Bassarova, Amanda Poissonnier, Marike Feenstra, Marta Nyakas, Bjarne Johannessen, Truls Ryder, Robert Hermann, Lars Frich, Arild Holth, Else Marit Inderberg, Henrik Jespersen, Vivi Ann Flørenes, Jon Amund Kyte, Gunhild M. Mælandsmo, Eivind Valen Egeland

  • May 4, 2026

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Biotech exec Jeremy Levin on the industry’s strategic turning point